| Document |
Document Title |
|
WO/1999/003873A2 |
In our research, 3-phenyl-1,2,4-dithiazoline-5-one is found to be a potential sulfur-transfer reagent. The efficiency and optimization of this new sulfur-transfer reagent was investigated by solid-phase syntheses of dinucleotide phosphor...
|
|
WO/1999/003861A1 |
1,2,4-Thiadiazine and 1,4-thiazine derivates represented by formula (I) wherein A, B, D, R?1¿, R?2¿, R?3¿ and R?4¿ are defined in the description, compositions thereof and methods for preparing the compounds are described. The compou...
|
|
WO/1999/002150A1 |
The invention relates to the use of $g(b)-alkoxyacrylates of formulae (IA) or (IB) wherein R, R?1¿, R?6¿, R?7¿, R?8¿, X and Z are as defined herein, as therapeutically active substances, especially in the treatment or prophylaxis of ...
|
|
WO/1999/000356A1 |
This invention relates to compounds of formula (I) which inhibit Factor Xa, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ame...
|
|
WO/1999/000133A1 |
There is disclosed a method for increasing retinal and optic nerve head blood velocity by topical application of a composition comprising carbonic anhydrase inhibitors and hypotonic xanthan gum to the eye.
|
|
WO/1999/000375A1 |
New substituted aminoheterocyclylamides have the formula (I), in which Het stands for one of the heterocycles (a), (b), (c) or (d) and R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, X?1¿, X?2¿, m and n have the meanings indicated in the descriptio...
|
|
WO/1998/058919A1 |
This invention concerns compounds of formula (I), the $i(N)-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein X is CH or N; R?1¿ is hydrogen, C¿1-6?alkyl, C¿1-6?alkyl...
|
|
WO/1998/056779A1 |
This invention relates to 4-sulfinyl benzamide compounds which are ligands, in particular, antagonists, of the Calcitonin Gene-Related Peptide ('CGRP') receptor. In addition, this invention relates to the treatment and prevention of dise...
|
|
WO/1998/055461A1 |
The invention relates to novel fluoromethoximino compounds, methods for producing the same and their use as pest-control agents, as well as to new intermediate products and several methods for producing said products.
|
|
WO/1998/054159A1 |
The invention relates to non-steroidal gestagens of general formula (I), wherein R?1� and R?2� are the same or different and stand for a hydrogen atom, a C�1?-C�5? alkyl group or a halogen atom, or together with the C atom of the...
|
|
WO/1998/054163A1 |
1,2,3-Thiadiazole derivatives of general formula (I) (wherein R?1� is hydrogen, halogen, (C�1?-C�6?) alkyl, phenyl or the like and R?2� is group (A) or (B), wherein R?3� is halogen, cyano or the like; R?4� is hydrogen, haloge...
|
|
WO/1998/052559A1 |
Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
|
|
WO/1998/052945A1 |
The invention relates to compounds of general formula (I) in which pyr represents pyridyl, quinoyl or isoquinoyl, which is optionally mono- or poly-substituted, and n is 1 or 2. Said compounds have a pronounced microbicidal action and ca...
|
|
WO/1998/051312A1 |
This invention provides novel derivatives of 2,3,5,6-tetrahydro-1,2,6-thiadiazin-3,5-dione 1,1-dioxide which are useful as ligand inhibitors for increasing levels of free corticotropin-releasing factor in the brain. Such ligand inhibitor...
|
|
WO/1998/050031A1 |
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R�1? is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L�2?-, and (i) heterocyclic -L�2?-;...
|
|
WO/1998/050029A1 |
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R�1? is (a) hydrogen, (b) lower alkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl -L�2?-, and (i) heterocyclic -L�2?...
|
|
WO/1998/050030A1 |
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R�1? is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L�2?-, and (i) heterocyclic-L�2?-; ...
|
|
WO/1998/049146A2 |
Certain derivatives of acridones and benzothiadiazines have been found to have anti-cancer properties by virtue of their specific inhibition of the cyclin D dependant kinase CDK4. These molecules inhibit CDK4 activity more than they inhi...
|
|
WO/1998/047885A1 |
Compounds of formula (I), processes for their preparation and their use as CNS agents are described, in which R?a� is a group of formula (i) in which P?1� is bicyclic aryl, or a bicyclic heterocyclic ring containing 1 to 3 heteroatom...
|
|
WO/1998/047933A1 |
Provided are certain transition metal complexes which are useful as catalysts in the polymerization of olefinic monomers. In particular, the invention provides complexes of certain bidentate ligands bonded to Ni, Pd, Co, or Fe, and optio...
|
|
WO/1998/047367A1 |
The new active substance combinations of 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropy
l]-2,4-dihydro-[1,2,4]-triazol-3-thione of formula (I) and of the active substances of groups (1) to (24) listed in the description hav...
|
|
WO/1998/046786A1 |
The present invention relates to a novel diverse library of aminothioether compounds and derivatives thereof, processes for the preparation thereof, and to an apparatus providing a readily accessible source of individual members of the l...
|
|
WO/1998/046631A1 |
The present invention relates to a novel diverse library of peptidomimetic macrocyclic compounds, processes for the preparation thereof, and to apparatus providing a readily accessible source of individual members of the library. The app...
|
|
WO/1998/045253A1 |
A series of activated iodo-benzamide derivatives are described as antineoplastic and antiviral drug compounds. The compounds generally possess a chelating group, a thio trapping group and an activating group. The presumptive mechanism of...
|
|
WO/1998/041515A1 |
The invention relates to novel compounds of formula I wherein X represents O or S, R?3� represents COOR?4�, CN, 1H-tetrazol-5-yl or CONHSO�2?R?5�, and at least one of R?2� or R?2'� means a substituent. Said compounds display ...
|
|
WO/1998/041521A1 |
The invention relates to new compounds of the formula I wherein Z, R?1�, R?2�, R?3�, and R?3'� have the meaning given in Claim 1. Said compounds display endothelin receptor antagonistic properties.
|
|
WO/1998/041513A2 |
The invention relates to new substituted aminosalicyclic acid amides of general formula (I), several methods for their production and their use as fungicides, as well as new intermediate products and several methods for their production.
|
|
WO/1998/040420A2 |
The present invention includes novel ligands which may be utilized as part of a catalyst system. A catalyst system of the present invention is a transition metal-ligand complex. In particular, the catalyst system includes a transition me...
|
|
WO/1998/040374A2 |
Methods for preparing olefin polymers, or oligomers catalysts for preparing olefin polymers and bidentate ligand used for preparing these catalysts are disclosed. The polymers can be prepared containing the corresponding monomers with a ...
|
|
WO/1998/039329A1 |
An amidoaromatic ring sulfonamide hydroxamic acid compound that $i(inter alia) inhibits matrix metalloprotease activity is disclosed, as are a treatment process that comprises administering a contemplated amidoaromatic ring sulfonamide h...
|
|
WO/1998/039312A1 |
o-Benzenedisulfonimide arenediazonium salts, of formula (1), can be prepared easily and have a very high stability. They can be used in the preparation of the organic compounds usually preparable from diazonium salts, through reactions w...
|
|
WO/1998/039006A1 |
The present invention is directed toward the use of the drug Troglitazone and related thiazolidinedione compounds in the treatment of the climacteric and cancer. This use is based on the novel discovery that Troglitazone inhibits steroid...
|
|
WO/1998/037877A1 |
Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes inc...
|
|
WO/1998/038181A1 |
Insecticidal and miticidal compounds of formula (I), wherein R is hydrogen, halogen, nitro, C�1?-C�8? alkyl, C�1?-C�8? alcoxyl, or C�1?-C�6? haloalkyl, compositions comprising these compounds, and methods for their use.
|
|
WO/1998/038163A1 |
Matrix metalloproteinases (MMPs) are a group of enzymes that have been implicated in the pathological destruction of connective tissue and basement membranes. These zinc containing endopeptidases consist of several subsets of enzymes inc...
|
|
WO/1998/038179A1 |
A family of compounds having general structural formula (I) wherein W is a reverse hydroxamic acid group (a); R�5? is hydrogen or lower alkyl; R�6? is (b); where Z�1? is heteroarylene; preferably: R�1? is methyl, ethyl, isopropyl...
|
|
WO/1998/035944A1 |
$g(a)-alkoxy and $g(a)-thioalkoxyamide compounds of formula (I) and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor...
|
|
WO/1998/035957A1 |
Amide derivatives having formula (I) or pharmaceutically acceptable salts thereof wherein R�1?-R�5? are each individually selected from the group of substituents including hydrogen, halogen, hydroxyl, thiol, lower alkyl, substituted ...
|
|
WO/1998/035950A1 |
Compounds of general structural formula (I) are shown to have AMPA receptor enhancing properties. The compounds are useful for such therapeutic purposes as facilitating the learning of behaviors dependent upon AMPA receptors, and in trea...
|
|
WO/1998/034929A1 |
The invention relates to certain 8-ureido and 8-thioureido 1,2-benzothiazines, 1,2,4-benzothioxazines and 1,2,4-benzothiodiazines useful in the treatment of disease states mediated by the chemokine, Interleukin-8.
|
|
WO/1998/033873A1 |
A composition of matter is disclosed having structure (I) wherein R and R?1� are independently a member selected from the group consisting of alkyl, cycloalkyl, aryl, aralkyl, and alkaryl; R?2� is an alkylene moiety; R?3� is hydrog...
|
|
WO/1998/032742A1 |
Amide derivatives represented by general formula (I), or their salts and medicinal compositions containing these derivatives and pharmaceutically acceptable carriers, wherein each symbol has the following meaning: A: heteroarylene; X: a ...
|
|
WO/1998/032439A1 |
This invention relates to novel compounds of Formula (I), and pharmaceutical compositions thereof, and methods of treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/1998/031686A1 |
A pharmaceutical compound of formula (I), in which R?1� is hydrogen, C�1-4? alkyl, C�1-4? alkoxy or halo, and R?2� is hydrogen, C�1-4? alkyl or C�1-4? alkoxy; or a salt thereof. The compounds of the invention and their pharma...
|
|
WO/1998/030561A1 |
The invention refers to novel 2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole derivatives of formula (I) having an influence on the heart and the central nervous system, furthermore pharmaceutical compositions containing the above derivatives,...
|
|
WO/1998/030539A1 |
Thiocarbamic acid derivatives which have a higher safety and a more excellent cholesterol resistance than those of conventional drugs and are characterized by being represented by general formula (1) or salts thereof (for example: O-(4-t...
|
|
WO/1998/029400A1 |
Compounds are disclosed having general formula (I), in which R?1�, R?2�, R?3� and R?4� independently represent hydrogen, optionally substituted alkyl, alkenyl, alkinyl or aryl; and Ar stands for optionally substituted aryl. These...
|
|
WO/1998/029399A1 |
The invention relates to ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention includes an anionic portion combined with at least one cationic portion M?+m� in sufficient numbers to ensur...
|
|
WO/1998/029388A1 |
The invention relates to ionic compounds in which the anionic load has been delocalized. A compound disclosed by the invention is comprised of an amide or one of its salts, including an anionic portion combined with at least one cationic...
|
|
WO/1998/029400A2 |
Compounds are disclosed having general formula (I), in which R?1�, R?2�, R?3� and R?4� independently represent hydrogen, optionally substituted alkyl, alkenyl, alkinyl or aryl; and Ar stands for optionally substituted aryl. These...
|
